Uluslararası HastaDuyurularİletişim
HACETTEPE ÜNİVERSİTESİHASTANELERİ
Randevu Al
TR
  1. Ana Sayfa
  2. Doktorlar
  3. Prof. Dr. Murat Tuncel
Prof. Dr. Murat Tuncel

Prof. Dr.

Murat Tuncel

Nükleer Tıp · Erişkin Hastanesi

Randevu Al

Eğitim

  1. 2005
    Nükleer Tıp
    Nükleer Tıp
  2. 2005
    Doktora — Nükleer Tıp
    Hacettepe Üniversitesi
  3. 2005
    Yüksek lisans — Nükleer Tıp
    Hacettepe Üniversitesi
  4. 2000
    Tıp Fakültesi
    Hacettepe
  5. 1993
    Atatürk Anadolu Lisesi

Yayınlar

Kaynak: Hacettepe Üniversitesi Akademik Veri Yönetim Sistemi (AVESİS) · Tüm yayınlar (184) ↗

Makaleler 123

  1. Intracholecystic Papillary Neoplasm Mimicking High-Grade Dedifferentiation in a Patient With Neuroendocrine Tumor: The Value of Dual-Tracer PET/CTSimsir C., YILMAZ K., Kılıçkap S., Onur R. M., TUNCEL M.Clinical Nuclear Medicine, cilt.51, sa.11, 2026 (SCI-Expanded, Scopus)
  2. Dual tracer PET/CT imaging for a patient with lipoadenoma: what Choline missed but Trivehexin revealedTUNCEL M., Kaya G., KODAZ O., YILDIRIM M. F., Gülkanat L. D.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.11, ss.6137-6138, 2026 (SCI-Expanded, Scopus)
  3. Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoidTUNCEL M., KÖKSAL D., DİKMEN E., Şimşir C., Pala A., AKTAŞ B. Y., et al.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.10, ss.5617-5618, 2026 (SCI-Expanded, Scopus)
  4. Molecular, Biochemical, and Bioimaging Markers of MEN SyndromesPetranović Ovčariček P., Calvello M., Hillebrand J. J., Huellner M. W., TUNCEL M., Lopci E., et al.Genes, cilt.17, sa.7, 2026 (SCI-Expanded, Scopus)
  5. Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative ReviewPetranović Ovčariček P., TUNCEL M., Huellner M. W., Campennì A., Giovanella L.Cancers, cilt.18, sa.12, 2026 (SCI-Expanded, Scopus)
  6. Marine-Lenhart syndrome: why nuclear medicine imaging remains essential for diagnosis and treatmentPetranović Ovčariček P., Ruggeri R. M., Campennì A., Corrêa Chaves Nunes I., Maccora D., TUNCEL M., et al.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.6, ss.4259-4269, 2026 (SCI-Expanded, Scopus)
  7. High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patientsTelli T., TUNCEL M., KARABULUT E., AKSOY S., ERMAN M., AKDOĞAN B., et al.Urologic Oncology: Seminars and Original Investigations, cilt.44, sa.4, 2026 (SCI-Expanded, Scopus)
  8. PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CTKaya G., AKIN S., BÜYÜKAŞIK Y., BOZKURT M. F., TUNCEL M., Kiratli P. O.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.4, ss.2325-2336, 2026 (SCI-Expanded, Scopus)
  9. The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progressPetranović Ovčariček P., Verburg F. A., de Keizer B., Campennì A., TUNCEL M., Kreissl M. C., et al.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.4, ss.2213-2216, 2026 (SCI-Expanded, Scopus)
  10. Dual-time-point 68Ga-FAPI PET/CT in gastrointestinal malignancies: head-to-head comparison with 18 F-FDG for lesion detection and patient-level assessmentPala H., TUNCEL M., YALÇIN Ş., KARABULUT E., AKKAPULU N., EROL T., et al.Annals of Nuclear Medicine, 2026 (SCI-Expanded, Scopus)
  11. Is there a need for dual radiotracer response evaluation for peptide receptor radionuclide therapy? ¿Es necesaria la evaluación de la respuesta con doble radiotrazador en la terapia con radionúclidos de receptores peptídicos?TUNCEL M., KÜÇÜKER C.Revista Espanola de Medicina Nuclear e Imagen Molecular, 2026 (SCI-Expanded, Scopus)
  12. Imaging Discordance Between [⁶⁸Ga]-PSMA PET and [¹⁷⁷Lu]-PSMA SPECT in mCRPCKÜÇÜKER C., Kaya G., ERGÜN E., UĞUR Ö., TUNCEL M.Clinical Nuclear Medicine, 2026 (SCI-Expanded, Scopus)
  13. Beyond metastases: a mechanism-based guide to misleading ¹³¹I uptake on whole-body scintigraphyGregov A., Deak A., Lučev L., Campennì A., Beintner-Skawran S., Giovanella L., et al.Annals of Nuclear Medicine, 2026 (SCI-Expanded, Scopus)
  14. Five-year follow-up of Estimabl 2 trail: a critical appraisalTUNCEL M., Ovcaricek P. P., Giovanella L.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.52, ss.4753-4756, 2025 (SCI-Expanded, Scopus)
  15. Validation of sentinel lymph node biopsy with completion neck dissection in oral cavity cancerPamuk A. E., Tellioğlu B., Eroğlu E., Kuşcu O., Süslü N., Tuncel M., et al.ACTA OTO-LARYNGOLOGICA, cilt.1, sa.1, ss.1-6, 2025 (SCI-Expanded, Scopus)
  16. Significant response to [225Ac]Ac-DOTATATE therapy in a patient with small cell lung cancerTUNCEL M., Turkan C., Eryilmaz Y., Pala A., Kilickap S.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.52, ss.2743-2744, 2025 (SCI-Expanded, Scopus)
  17. The Randomized, Phase 2 Trial LuCAP Study.Tuncel M., Kaya G., Kodaz O., Türkan C., Çağlar Tuncalı M.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, cilt.66, sa.6, ss.984-985, 2025 (SCI-Expanded, Scopus)
  18. Multinational Attitudes Toward AI in Health Care and Diagnostics Among Hospital PatientsBusch F., Hoffmann L., Xu L., Zhang L. J., Hu B., Garcia-Juarez I., et al.JAMA NETWORK OPEN, cilt.8, sa.6, 2025 (SCI-Expanded, Scopus)
  19. 68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and PerspectivesUrso L., Napolitano R., Speltri G., TUNCEL M., Badrane I., Uccelli L., et al.CANCERS, cilt.17, sa.9, 2025 (SCI-Expanded, Scopus)
  20. Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence-A Systematic Review and Meta-AnalysisHoffmann M. A., SOYDAL Ç., Virgolini I., TUNCEL M., Kairemo K., Kapp D. S., et al.CANCERS, cilt.17, sa.5, 2025 (SCI-Expanded, Scopus)
  21. Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancerAKYILDIZ A., Ismayilov R., Abdurrahimli N., Ormanci A., GÜVEN D. C., TUNCEL M., et al.JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.55, sa.2, ss.100-105, 2025 (SCI-Expanded, Scopus)
  22. Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patientsYilmaz Y., Ozercan M. M., Ancin B., DİKMEN Z. G., ÇAĞLAR TUNCALI M., TUNCEL M., et al.BIOMARKERS IN MEDICINE, cilt.19, sa.7, ss.259-265, 2025 (SCI-Expanded, Scopus)
  23. Radioiodine-refractory thyroid cancer-is it time to change the definition in light of novel redifferentiation therapies?Ovcaricek P. P., de Keizer B., Campenni A., Kreissl M. C., Deandreis D., TUNCEL M., et al.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.52, sa.2, ss.380-385, 2025 (SCI-Expanded, Scopus)
  24. Redifferentiation Therapies in Thyroid Oncology: Molecular and Clinical AspectsOvcaricek P. P., TUNCEL M., Aghaee A., Campenni A., Giovanella L.JOURNAL OF CLINICAL MEDICINE, cilt.13, sa.23, 2024 (SCI-Expanded, Scopus)
  25. Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter seriesGiovanella L., Milan L., Roll W., Weber M., Schenke S., Kreissl M., et al.CLINICAL CHEMISTRY AND LABORATORY MEDICINE, cilt.62, ss.2307-2315, 2024 (SCI-Expanded, Scopus)
  26. Theranostics of Thyroid CancerGiovanella L., TUNCEL M., Aghaee A., Campenni A., Petranović Ovčariček P., De Virgilio A.Seminars in Nuclear Medicine, cilt.54, sa.4, ss.470-487, 2024 (SCI-Expanded, Scopus)
  27. Plasmacytoma and Amyloid Lymphadenopathy, FDG, and Fluorocholine.Kaya G., Akin S., Tuncel M., Kiratli P.Clinical nuclear medicine, cilt.49, ss.559-560, 2024 (SCI-Expanded, Scopus)
  28. The European Association of Nuclear Medicine (EANM)’s Response to the 2023 European Thyroid Association (ETA) clinical practice guidelines for thyroid nodule management and nuclear medicine: a deliberate oversight?Kreissl M. C., Ovčariček P. P., Campenni A., Vrachimis A., TUNCEL M., Giovanella L.European Journal of Nuclear Medicine and Molecular Imaging, cilt.51, sa.6, ss.1678-1681, 2024 (SCI-Expanded, Scopus)
  29. P-20 Primary hyperparathyroidism associated with maltoma of the thyroid gland: imaging challengesErturk B., Kaya G., Tuncel M., Ergin M. I., Haznedaroglu I. C., Uner A., et al.JCEM Case Reports, cilt.2, sa.Supplement_1, ss.13-14, 2024 (Hakemli Dergi)
  30. Integrated Diagnostics of Thyroid NodulesGiovanella L., Campennì A., Tuncel M., Petranović Ovčariček P.CANCERS, cilt.16, sa.2, ss.311-322, 2024 (SCI-Expanded, Scopus)
  31. Bilgisayarlı Tomografi, Pozitron Emisyon Tomografisi ve Nükleer Manyetik Rezonans Görüntülemede Temel Kavram ve İlkeler.BAYARI S. H., AKIN S., TUNCEL M.Batı Karadeniz Tıp Degisi, cilt.7, sa.3, ss.269-278, 2023 (TRDizin)
  32. Molecular Pathological Markers and TERT Promoter Mutations: Correlations with Clinicopathological Features and Distant Metastasis in Turkish Patients with Papillary Thyroid CarcinomaYILMAZ E., Güler G., KURTULAN O., Karakaya J., TELLİ T., TUNCEL M., et al.Endocrinology Research and Practice, cilt.27, sa.4, ss.191-198, 2023 (Scopus, TRDizin)
  33. Unexpected Axillary Lymph Node Uptake During Lower-Limb Lymphoscintigraphy in a Case With Vulvar Lymphangioma CircumscriptumSOYDAŞ TURAN B., TUNCEL M.Clinical nuclear medicine, cilt.48, sa.10, ss.879-880, 2023 (SCI-Expanded, Scopus)
  34. Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancervon Eyben R., Hoffmann M. A., SOYDAL Ç., Virgolini I., TUNCEL M., Gauthé M., et al.Biomedicines, cilt.11, sa.9, 2023 (SCI-Expanded, Scopus)
  35. Evaluation of efficacy of tumor-specific nanoliposomal radiosensitizer in radiotherapyKarabuga M., ERDOĞAN S., Filikci K., Hazıroglu R., TUNCEL M., CENGİZ M.Journal of Drug Delivery Science and Technology, cilt.86, 2023 (SCI-Expanded, Scopus)
  36. Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer.Petranović Ovčariček P., Campenni A., de Keizer B., Deandreis D., Kreissl M. C., Vrachimis A., et al.Cancers, cilt.15, sa.17, 2023 (SCI-Expanded, Scopus)
  37. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.Giovanella L., Milan L., Roll W., Weber M., Schenke S., Kreissl M., et al.European journal of nuclear medicine and molecular imaging, cilt.50, sa.9, ss.2767-2774, 2023 (SCI-Expanded, Scopus)
  38. Value of Dynamic (18)F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study.Kupik O., Tuncel M., Özgen Kıratlı P., Akpınar M. G., Altundağ K., Başaran Demirkazık F., et al.Molecular imaging and radionuclide therapy, cilt.32, sa.2, ss.94-102, 2023 (Scopus, TRDizin)
  39. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational studyTelli T., Tuncel M., Karabulut E., Aksoy S., Erman M., Akdogan B., et al.PROSTATE, cilt.83, sa.8, ss.792-800, 2023 (SCI-Expanded, Scopus)
  40. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.Telli T., Tuncel M., Karabulut E., Aksoy S., Erman M., Akdogan B., et al.The Prostate, cilt.83, ss.792-800, 2023 (SCI-Expanded, Scopus)
  41. Quality Goal for Salvage Treatment for Patients with Prostate Cancer at Prostate-specific Antigen Relapse.von Eyben R., Hoffmann M. A., Kapp D. S., Soydal C., Uprimny C., Virgolini I., et al.European urology oncology, cilt.5, ss.732-733, 2022 (SCI-Expanded, Scopus)
  42. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis.von Eyben R., Kapp D. S., Hoffmann M. A., Soydal C., Uprimny C., Virgolini I., et al.Cancers, cilt.14, sa.21, 2022 (SCI-Expanded, Scopus)
  43. SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management-the EANM perspectiveOvcaricek P. P., Kreissl M. C., Campenni A., de Keizer B., Tuncel M., Vrachimis A., et al.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.49, sa.12, ss.3959-3963, 2022 (SCI-Expanded, Scopus)
  44. FDG-PET/CT Imaging of Large Vessel VasculitisKaya G., Tuncel M.Acta Medica, cilt.53, ss.37-44, 2022 (Hakemli Dergi)
  45. Diagnostic Performance of(99)mTc-methoxy-isobutyl-isonitrile (MIBI) Imaging in Hypofunctioning Thyroid Nodules: A European Multicenter StudySchenke S., Campenni A., Tuncel M., Piccardo A., Sager S., Crncic T. B., et al.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.49, sa.SUPPL 1, 2022 (SCI-Expanded, Scopus)
  46. Cerebellar Hypermetabolism: An Alternative Marker for Diagnosis of Paraneoplastic Cerebellar Degeneration.Arslan D., Ardıc F. S., Gultekin-Zaim O. B., Tuncel M., Kertmen N., Gocmen R., et al.Neurologia (Barcelona, Spain), 2022 (Hakemli Dergi)
  47. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment.Tuncel M., Vrachimis A., Campenni A., de Keizer B., Verburg F. A., Kreissl M. C., et al.European journal of nuclear medicine and molecular imaging, cilt.49, sa.10, ss.3316-3319, 2022 (SCI-Expanded, Scopus)
  48. Diagnostic Performance of Tc-99m-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter StudySchenke S. A., Campenni A., TUNCEL M., Bottoni G., Sager S., Bogovic Crncic T., et al.DIAGNOSTICS, cilt.12, sa.6, 2022 (SCI-Expanded, Scopus)
  49. Role of indocyanine green combined with radiotracer-Technetium 99 m in neck surgery for primary and recurrent head and neck cancer: preliminary results of a tertiary cancer centerSuslu N. S., KATAR O., TUNCEL M.EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, cilt.279, sa.3, ss.1549-1560, 2022 (SCI-Expanded, Scopus)
  50. Predictive Value of Dual-phase F-18-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance ImagingKupik O., TUNCEL M., Kiratli P. O., GÜLSÜN AKPINAR M., Altundag K., DEMİRKAZIK F., et al.TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.37, ss.426-435, 2022 (ESCI, Scopus, TRDizin)
  51. 18F FDG PET/CT after Neoadjuvant Chemotherapy and Pathological Responses are Predictive Factors for Disease-Free Survival and Overall Survival in Patients with Locally Advanced Breast Cancer: A Prospective StudyKupik O., TUNCEL M., AKSOY S., Kiratli P. O., GÜLSÜN AKPINAR M., Altundag K., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.3, ss.150-158, 2022 (SCI-Expanded, Scopus)
  52. 68Ga-DOTATATE PET/CT in Pituitary Carcinoma.Kaya G., Soydas Turan B., Dagdelen S., Berker M., Tuncel M.Clinical nuclear medicine, cilt.46, ss.996-998, 2021 (SCI-Expanded, Scopus)
  53. Treatment of Glucagonoma-Related Necrolytic Migratory Erythema With Peptide Receptor Radionuclide Therapy.Mavi M. E., Tuncel M.Clinical nuclear medicine, cilt.46, ss.1002-1003, 2021 (SCI-Expanded, Scopus)
  54. A multicenter survey of current practices of Tc-99m-methoxy-isobutyl-isonitrile (MIBI) imaging for the diagnosis of thyroid nodules: more standardization is essentialSchenke S. A., Campenni A., TUNCEL M., Piccardo A., Sager S., Crncic T. B., et al.CLINICAL AND TRANSLATIONAL IMAGING, cilt.9, sa.5, ss.413-422, 2021 (SCI-Expanded, Scopus)
  55. Clinical parameters and nomograms for predicting lymphnode metastasis detected with 68Ga-PSMA-PET/CTOnal C., Ozyigit G., Oymak E., Guler O. C., Hurmuz P., Tilki B., et al.RADIOTHERAPY AND ONCOLOGY, cilt.161, 2021 (SCI-Expanded, Scopus)
  56. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.Onal C., Ozyigit G., Oymak E., Guler O. C., Hurmuz P., Tilki B., et al.The Prostate, cilt.81, ss.648-656, 2021 (SCI-Expanded, Scopus)
  57. Predictive factors of tumor sink effect: Insights from Lu-177-Prostate-specific membrane antigen therapyTUNCEL M., TELLİ T., ÇAĞLAR TUNCALI M., KARABULUT E.ANNALS OF NUCLEAR MEDICINE, cilt.35, sa.5, ss.529-539, 2021 (SCI-Expanded, Scopus)
  58. Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancerKarpuz M., Silindir-Gunay M., Ozer A. Y., Ozturk S. C., Yanik H., Tuncel M., et al.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.156, 2021 (SCI-Expanded, Scopus)
  59. Colonic Visualization of Tc-99m-DMSA Due to Enterovesical FistulaTELLİ T., KAYA G., IŞIK Z., TUNCEL M.CLINICAL NUCLEAR MEDICINE, cilt.46, sa.1, ss.66-68, 2021 (SCI-Expanded, Scopus)
  60. Non-ultrasonographic and Non-radioiodine Imaging Techniques in Thyroid CancerTUNCEL M.NUCLEAR MEDICINE SEMINARS, cilt.7, 2021 (Hakemli Dergi)

AVESİS'te 123 kaydın tamamı →

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 51

  1. Imaging Armamentarium of Hyperparathyroidism; New Player FCH PET-CT-USTUNCEL M., Kaya G., Caglar M., Kaynaroglu V., CENNET Ö., ÜNLÜTÜRK U., et al.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 19 - 23 Ekim 2024, (Özet Bildiri)
  2. An Extremely Rare MEN4 case with Multimodality ImagingKODAZ O., Kaya G., TUNCEL M., Tuncali M. C.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 19 - 23 Ekim 2024, (Özet Bildiri)
  3. Radiolabelling of Gallium-68 DTPA and EDTA used for Kidney Imaging- Molaei A., SARCAN BOZKIR E. T., ERDOĞAN S., TUNCEL M.International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, İzmir, Türkiye, 04 Mayıs 2023, (Özet Bildiri)
  4. Is It Safe Enough to Follow-up Patients Only with Post-therapy Whole-body Scan After PRRT?Telli T., Tuncel M., Kiratli P. O.33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), ELECTR NETWORK, 22 - 30 Ekim 2020, cilt.47, (Özet Bildiri)
  5. Akciğer Kanseri nedeniyle rezeksiyon uygulanan hastalarda doku yapıştırıcı kullanımı yalancı PET pozitifliğine neden oluyor mu?DOĞAN R., UYSAL S., KÖKSAL D., KUMBASAR U., TUNCEL M.Girişimsel Onkoloji Toplantısı – Multidisipliner Tedavi Yaklaşımı, Ankara, Türkiye, 13 - 15 Aralık 2019, (Özet Bildiri)
  6. The Role of FDG PET/CT Detecting Bone Marrow Involvement in Non-Hodgkin's Lymphoma PatientsKUPIK O., Akin S., TUNCEL M., TÜRKER A., Kars A., Erbas B.31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Düsseldorf, Almanya, 13 - 17 Ekim 2018, cilt.45, (Özet Bildiri)
  7. Yavaş büyüyen soliter pulmoner nodül: Adenoleiomyomatöz HamartomBABAOĞLU E., SARINÇ ULAŞLI S., ÖNDER S. Ç., TUNCEL M., KÖKSAL D.Ulusal Akciğer Sağlığı KOngresi, Türkiye, 14 - 18 Mart 2018, (Özet Bildiri)
  8. FDG PET-CT parameters in the therapy evaluation of patients with Hodgkin's lymphomaTUNCEL M., Kutluk T. M., Kiratli P. O., AYDIN B., Erbas B., AKYÜZ C.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri)
  9. Tuncel M Kurucu N Kıratlı PÖ Erbaş B Akyüz C Clinical Impact of FDG PET CT in pediatric soft tissue sarcoma Eur J Nucl Med Mol ImagingTUNCEL M., KURUCU N., ÖZGEN KIRATLI M. P., ERBAŞ H. B., AKYÜZ C.Annual Congress of the European Association of the Nucleer Medicine, Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, ss.206, (Özet Bildiri)
  10. The clinical role of Ga-68 DOTATE PET-CT in patients with neuroendocrine tumorsTUNCEL M., KILIÇKAP S., Akdemir E.28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)
  11. Clinical impact of FDG PET-CT in pediatric soft tissue sarcomasTUNCEL M., KURUCU N., Kiratli P. O., Erbas B., AKYÜZ C.28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)
  12. Practical measures of dynamic 18 FDG time-activiy curves.TUNCEL M., Kupik O., Kiratli P., Erbas B.28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)
  13. Value of FDG PET-CT in the therapy evaluation of Hodgkin's lymphomaTUNCEL M., Kutluk T. M., Kiratli P. O., AYDIN B., Erbas B., AKYÜZ C.28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)
  14. Time-dependent reduction of liver 18 FDG activity in the dual-phase 18 FDG PET/CT studyKupik O., TUNCEL M., Kiratli P., Erbas B.28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)
  15. Intrakranial Germ Hücreli Tümör Tanısı Alan Hastaların Değerlendirilmesi SP10TUNCEL M., KURUCU N., ÖZGEN KIRATLI M. P., ERBAŞ H. B., AKYÜZ C.21. Ulusal Kanser Kongresi, Antalya., Antalya, Türkiye, 22 - 26 Mayıs 2015, (Özet Bildiri)
  16. Clinical impact of Ga-68-DOTATATE in patients with neuroendrocrine tumorsTUNCEL M., KILIÇKAP S., Akdemir E.3rd Theranostics World Congress on Gallium-68 and PRRT, Maryland, Amerika Birleşik Devletleri, 12 - 14 Mart 2015, cilt.56, (Özet Bildiri)
  17. Predictive value of semi-quantitative parameters of 18 FDG PET/CT for bone marrow involvement in patients with non-Hodgkin lymphoma.TUNCEL M., Kupik O., Babacan T., ÜNER A., TÜRKER A., Kars A., et al.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Gothenburg, İsveç, 18 - 22 Ekim 2014, cilt.41, (Özet Bildiri)
  18. Do semi-quantitative parameters, obtained from PET and CT component of PET/CT study, help for the differential diagnosis between anemia related changes vs. bone marrow involvement?TUNCEL M., Kupik O., Babacan T., ÜNER A., TÜRKER A., Kars A., et al.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Gothenburg, İsveç, 18 - 22 Ekim 2014, cilt.41, (Özet Bildiri)
  19. Application of dynamic 18FDG PET/CT study: semi-quantitative parameters for the evaluation of perfusion and metabolism of lung lesions.TUNCEL M., Kupik O., Erbas B.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Gothenburg, İsveç, 18 - 22 Ekim 2014, cilt.41, (Özet Bildiri)
  20. Spinal cord visualization in children on 18FDG PET/CT studyKupik O., TUNCEL M., Erbas B.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, Fransa, 19 - 23 Ekim 2013, cilt.40, (Özet Bildiri)
  21. Comparison of different metabolic parameters used in dual phase FDG PET imagingTUNCEL M., Kupik O., Akdemir E., Erbas B.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, Fransa, 19 - 23 Ekim 2013, cilt.40, (Özet Bildiri)
  22. The perfusion and metabolic characteristics of various tumors as assesed by dynamic FDG PETTUNCEL M., Kupik O., Erbas B.Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, Fransa, 19 - 23 Ekim 2013, cilt.40, (Özet Bildiri)
  23. Role of Ventilation-Perfusion Scintigraphy in the Evaluation of Pulmonary HypertensionKiratli P. O., TUNCEL M., Temelli B., Akdogan A.23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Avusturya, 9 - 13 Ekim 2010, cilt.37, (Özet Bildiri)
  24. SPECT-CT offers high diagnostic accuracy when findings on planar bone scintigraphy are inconclusiveCaglar M., Velipasaoglu Z., TUNCEL M.23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Avusturya, 9 - 13 Ekim 2010, cilt.37, (Özet Bildiri)
  25. Iopromide and Tc 99m loaded nano sized tumor targeted liposomes for tumor imaging by SPECT CTERDOĞAN S., SİLİNDİR GÜNAY M., Ozer A. Y., Dogan A. l., TUNCEL M., Ugur Ö.European Science Foundation (ESF) Research Congress, Nanomedicine: Reality Now and Soon, 23 - 28 Ekim 2010, (Özet Bildiri)
  26. Development Of Novel Nano Sized Liposomal Contrast Agents For Tumor Diagnosis By SPECT CT Preparation Characterization And In Vitro Tumor Cell BindingSİLİNDİR GÜNAY M., ERDOĞAN S., Ozer A. Y., Dogan A. L., TUNCEL M., Ugur Ö.15th International Pharmaceutical Technology Symposium (IPTS-15), 13 - 15 Eylül 2010, (Tam Metin Bildiri)
  27. Tumor Targeted Nanosized Liposome Based Diagnostic Agents for Hybrid Imaging SystemsSİLİNDİR GÜNAY M., ERDOĞAN S., A Yekta O., Ozer A. Y., Dogan A. L., TUNCEL M.3rd BBBB Conference on Pharmaceutical Sciences, 26 - 29 Ekim 2009, (Tam Metin Bildiri)
  28. Characterization and In Vitro Cell Uptake of Nanosized Liposome Based Diagnostic Agents For Hybrid Imaging SystemsSİLİNDİR GÜNAY M., ERDOĞAN S., Ozer A. Y., Dogan A. L., TUNCEL M., Ugur Ö.Symposium on Phospholipids in Pharmaceutical Research, 11 - 12 Haziran 2009, (Özet Bildiri)
  29. Gallium-68 Radiolabelled PD-L1 Binding Peptide WL12 for Lung CancerErgün G. Ş., Sarcan Bozkır E. T., Erdoğan S., Tuncel M., Uğur Ö.
  30. LYSO TABANLI YÜKSEK ÇÖZÜNÜRLÜKLÜ PREKLİNİK PET-BT CİHAZI KABUL TESTLERİNİN UYGULANMASI VE SONUÇLARIÖzpelitoğlu M. Y., Demir Arıkan F. G., Kaya G., Kılıç E. C., Tuncel M., Uğur Ö.
  31. Clinical Significance of Bayesian penalized-likelihood and Motion Correction PET Reconstruction AlgorithmsKaya G., Pala H., Tuncel M., Uğur Ö.
  32. KHDAK Olgularında İnsan Epididim Proteini (HE4) Düzeyi ile PET Parametreleri Arasındaki Korelasyonun DeğerlendirilmesiYILMAZ Y., ÖZERCAN M. M., ANCIN B., DİKMEN Z. G., KILIÇKAP S., ÇAĞLAR TUNCALI M., et al.
  33. Factors that could predict tumour sink effect: Experience with Lu177 Prostatespecific membrane antigen therapyTuncel M., Telli T., Tuncali M., Karabulut E.cilt.48, (Özet Bildiri)
  34. Do ultrasound elastography and thyroid imaging reporting and data systems correctly classify hyperfunctioning nodules on thyroid scintigraphy?Tuncel M., Turan B. S., Isik Z.cilt.48, (Özet Bildiri)
  35. Interpreting Clinical Parameters and Nomograms for Predicting Lymph Node Metastasis Detected with 68 Ga-PSMAPET/CT in prostate cancer patientsOnal C., Ozyigit G., Oymak E., Guler O. C., Hurmuz P., Tilki B., et al.
  36. Interpreting Clinical Parameters and Nomograms for Predicting Lymph Node Metastasis Detected with 68 Ga-PSMAPET/CT in prostate cancer patientsÖNAL H. C., ÖZYİĞİT G., Oymak E., GÜLER O. C., HÜRMÜZ P., TİLKİ B., et al.
  37. Efficacy of Lu-177-PSMA-617 Therapy in Metastatic Castration-resistant Prostate Cancer Patients, A Single-Center ExperienceTelli T., Tuncel M., Caglar M.
  38. Clinical Impact Of [Ga-68]Ga-DOTA-TATE Imaging In Patients With Medullary Thyroid CancerTuncel M., Kilickap S., Suslu N.
  39. Predictors of Intertumoral Heterogeneity of F-18-FDG and Ga-68-PSMA Uptake in Patients with Prostate CancerTelli T., Tuncel M., Caglar M.
  40. In vitro and In vivo Diagnostic and Therapeutic Evaluation of Folate-Targeted, Paclitaxel and Vinorelbine Encapsulated Theranostıc Liposomes in Non-Small Cell Lung CancerKarpuz M., Silindir Günay M., Öztürk S. C., Yanık H., Tuncel M., Esendağlı G., et al.
  41. How accurate is serum thyroglobulin measurement in patients with differentiated thyroid cancer?TUNCEL M., TELLİ T., Tuncali M. C.
  42. The Role of (68)ga-PSMA-PET/CT in Pelvic FIELD Delineation in Prostate Cancer Patients with Pelvic Lymph Node MetastasisOnal C., HÜRMÜZ P., Torun N., TUNCEL M., Guler O. C., Reyhan M., et al.
  43. Integration of (68)ga-PSMA-PET/BT in Radiation Therapy Planning for Prostate Cancer Patients: A Multi-Institutional AnalysisOnal C., Torun N., HÜRMÜZ P., Guler O. C., TUNCEL M., Yildirim B. A., et al.
  44. Slowly progressive disease a new therapy response criteria? Lessons from tyrosine kinase inhibitor therapyTUNCEL M.
  45. Predictive value of dynamic and dual-phase 18 FDG PET/CT parameters in the assessment of neoadjuvant chemotherapy response in locally advanced breast cancer: A comperative study with dynamic contrast enhanced MRIKupik O., TUNCEL M., Kiratli P., Akpinar M., Altundag K., DEMİRKAZIK F., et al.
  46. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of prostate cancerAkdemir E., TUNCEL M., Tuncali M. C., BİLEN C. Y., Akyol F., Baydar D., et al.
  47. Predictive value of dynamic and dual 18 FDG PET/CT parameters in the assessment of neoadjuvant chemotherapy response in locally advanced breast cancer: A comparative study with contrast enhanced dynamic MRIKupik O., TUNCEL M., Kiratli P., Akpinar M., Altundag K., DEMİRKAZIK F., et al.
  48. Dynamic 18FDG PET/CT and dynamic contrast enhanced MRI of locally advanced breast cancer. Comparison of semi-quantitative functional and metabolic parameters.Kupik O., TUNCEL M., DEMİRKAZIK F., Akpinar M., Altundag K., Erbas B.
  49. The role of FDG PET-CT in the evaluation of patients with colorectal cancer. Interobserver studyTUNCEL M., Vargol S. E., Bariskanat N., Topbas E.
  50. The value of thyroglobulin levels in the fine needle biopsy aspirate of suspicious lymph nodes in patients with thyroid cancerTUNCEL M., Tuncali M. C.
  51. Utility of serum thyroglobulin, TC-99m thyroid scintigraphy, neck I-131 uptake and ultrasonography for the evaluation of patients with thyroid cancer after surgeryCaglar M., Temelli B., Kanat N. B., TUNCEL M., Vargol S. E.

Kitaplar 10

  1. RadyoimmünoterapiTUNCEL M., ÖZGEN KIRATLI M. P.Radyonüklit Tedavi, Bekiş R, Polack B, Bozkurt MF, Editör, O’xxTIP, İzmir, ss.443-456, 2019
  2. Nuclear Medicine Techniques in the diagnosis and treatment of diseases of the musculoskeletal systemÖMÜR Ö., TUNCEL M., UĞUR Ö.Musculoskeletal Research and Basic Science, Feza Korkusuz, Editör, Springer, New York, ss.213-257, 2016
  3. Nuclear Medicine Techniquesin the Diagnosis and Treatment of Diseases of the Musculoskeletal SystemTUNCEL M., ÖMÜR Ö., kapulu c. D., UĞUR Ö.Musculoskeletal Research and Basic Science, Feza Korkusuz, Editör, Springer, ss.213-255, 2016
  4. OTIP kitapevi Bas boyun tümörlerinde PET/BT Murat TuncelTUNCEL M.Onkolojide PET/BT, Prof. Dr. Berna Polack, Editör, OTIP, ss.51-65, 2016
  5. Serebral palside nükleer (moleküler) görüntülemeTUNCEL M., BOZKURT M.Serebral palsi, Mintaze KErem Günel, Banu Anlar, Editör, Pelikan, Ankara, ss.133-140, 2015
  6. Ultrasonography and Fine-Needle Aspiration Cytology of Parathyroid GlandsTUNCEL M.
  7. Thyroid imagingGiovanella L., Campenni’ A., TUNCEL M., Ovčariček P. P.
  8. Anatomy and Embryology of Parathyroid GlandsKaya G., TUNCEL M.
  9. Kanser Ağrısında Radyofarmasötik TedaviKaya G., Tuncel M.
  10. Prostate Specific Membrane Antigen Based ImagingTUNCEL M.

İletişim

Bölüm
Nükleer Tıp, Erişkin Hastanesi
Konuştuğu diller
İngilizce, Almanca

Son güncelleme: